Safety and Effectiveness of Tofogliflozin in Japanese Patients with Type 2 Diabetes Mellitus in Real-world Practice: Results of 12-month Interim Analysis of a Long-term Post-marketing Surveillance Study (J-STEP/LT)

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2019 Jun 15

PMID 31197929

Citations 4

Authors

Kazunori Utsunomiya

Masayuki Senda

Seigo Kakiuchi

Hiroyuki Kameda

Masahiro Tamura

Yuji Kurihara

Ryoji Gunji

Shoko Fujii

Kohei Kaku

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: Due to the paucity of tofogliflozin data, we assessed the safety and effectiveness of tofogliflozin among Japanese patients with type 2 diabetes mellitus in the clinical setting, stratifying the patients by age, sex, estimated glomerular filtration (eGFR) rate and body mass index. We report the results of a 12-month interim analysis.

Materials And Methods: This was a 3-year prospective, observational and multicenter post-marketing study (Japanese Study of tofogliflozin with type 2 diabetes mellitus Patients/Long Term).

Results: Out of 6,897 patients enrolled, the safety and effectiveness analysis populations consisted of 6,712 and 6,449 patients, respectively. During 12 months, adverse drug reactions and their incidence were 9.12 and 0.88%, respectively. The incidence of hypoglycemia was 0.67%. Polyuria/pollakiuria occurred more frequently in patients aged ≥65 years than in patients aged <65 years. Women experienced higher rates of urinary tract and genital infection than men. The lowest eGFR subgroup experienced maximum volume depletion-related events. Cardiovascular and cerebrovascular disorders occurred in 0.55% of the patients. Glycated hemoglobin (HbA1c) and bodyweight significantly decreased by -0.76% and -2.73 kg, respectively, from baseline to the last observation carried forward (P < 0.0001). Except for the lowest eGFR subgroup, other eGFR subgroups showed significantly decreased HbA1c values. All eGFR subgroups showed significantly decreased bodyweight, and all body mass index subgroups showed significantly decreased HbA1c and bodyweight.

Conclusions: Our interim 12-month data suggest that tofogliflozin could be used safely and effectively in Japanese patients with type 2 diabetes mellitus, as tofogliflozin was well tolerated with low hypoglycemia risk, and significantly improved HbA1c and bodyweight.

Citing Articles

Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin.

Ito H, Inoue H, Izutsu T, Matsumoto S, Antoku S, Yamasaki T PLoS One. 2023; 18(9):e0292014.

PMID: 37733761 PMC: 10513294. DOI: 10.1371/journal.pone.0292014.

Renal outcomes with sodium-glucose cotransporters 2 inhibitors.

Sun X, Wang G Front Endocrinol (Lausanne). 2022; 13:1063341.

PMID: 36531469 PMC: 9752889. DOI: 10.3389/fendo.2022.1063341.

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).

Utsunomiya K, Koshida R, Kakiuchi S, Senda M, Fujii S, Kurihara Y J Diabetes Investig. 2020; 12(2):184-199.

PMID: 32597517 PMC: 7858109. DOI: 10.1111/jdi.13333.

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).

Utsunomiya K, Senda M, Kakiuchi S, Kameda H, Tamura M, Kurihara Y J Diabetes Investig. 2019; 11(1):132-141.

PMID: 31197929 PMC: 6944822. DOI: 10.1111/jdi.13097.

References

Nakamura I, Maegawa H, Tobe K, Tabuchi H, Uno S . Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study. Expert Opin Pharmacother. 2017; 19(3):189-201. DOI: 10.1080/14656566.2017.1408792. View

Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C . Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74. DOI: 10.1159/000364909. View

Ferrannini E, Veltkamp S, Smulders R, Kadokura T . Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013; 36(5):1260-5. PMC: 3631866. DOI: 10.2337/dc12-1503. View

Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A . Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin Ther. 2016; 38(1):66-88.e20. DOI: 10.1016/j.clinthera.2015.10.025. View

Zinman B, Inzucchi S, Lachin J, Wanner C, Fitchett D, Kohler S . Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke. 2017; 48(5):1218-1225. PMC: 5404404. DOI: 10.1161/STROKEAHA.116.015756. View

Leiter L, Langslet G, Vijapurkar U, Davies M, Canovatchel W . Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. Diabetes Ther. 2016; 7(2):269-78. PMC: 4900973. DOI: 10.1007/s13300-016-0163-1. View

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K . Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group.... Cardiovasc Diabetol. 2014; 13:65. PMC: 4021346. DOI: 10.1186/1475-2840-13-65. View

Utsunomiya K, Shimmoto N, Senda M, Kurihara Y, Gunji R, Fujii S . Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study). J Diabetes Investig. 2017; 8(6):766-775. PMC: 5668483. DOI: 10.1111/jdi.12626. View

Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K . Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). Diabetes Obes Metab. 2018; 20(5):1176-1185. PMC: 5947124. DOI: 10.1111/dom.13213. View

10.

Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T . Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012; 341(3):692-701. DOI: 10.1124/jpet.112.191593. View

11.

Santos L, de Lima F, Sousa-Rodrigues C, Barbosa F . Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Rev Assoc Med Bras (1992). 2017; 63(7):636-641. DOI: 10.1590/1806-9282.63.07.636. View

12.

. 8. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2017; 41(Suppl 1):S73-S85. DOI: 10.2337/dc18-S008. View

13.

Poole R, Prossler J . Tofogliflozin: first global approval. Drugs. 2014; 74(8):939-44. DOI: 10.1007/s40265-014-0229-1. View

14.

Kaku K, Lee J, Kaspers S, Woerle H, George J . Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Stroke　- Reply. Circ J. 2017; 81(6):899. DOI: 10.1253/circj.CJ-17-0395. View

15.

Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S . SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice. Diabetes Ther. 2018; 9(5):1757-1773. PMC: 6167302. DOI: 10.1007/s13300-018-0471-8. View

16.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

17.

Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K . Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter,.... Expert Opin Pharmacother. 2014; 15(6):749-66. DOI: 10.1517/14656566.2014.887680. View

18.

Utsunomiya K, Senda M, Kakiuchi S, Kameda H, Tamura M, Kurihara Y . Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). J Diabetes Investig. 2019; 10(5):1272-1283. PMC: 6717810. DOI: 10.1111/jdi.13017. View

19.

Inagaki N, Kondo K, Yoshinari T, Kuki H . Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study. J Diabetes Investig. 2015; 6(2):210-8. PMC: 4364856. DOI: 10.1111/jdi.12266. View

20.

DeFronzo R, Davidson J, Del Prato S . The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2011; 14(1):5-14. DOI: 10.1111/j.1463-1326.2011.01511.x. View